COMMENTARY

• Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
  October 13, 2021

• 5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
  September 29, 2021

• CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
  August 3, 2021

• Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
  July 12, 2021

• Updated Heart Failure Guidelines Position Entresto, SGLT2 Inhibitors as New Treatment Strategy Options
  June 22, 2021

• Battle Looming over 2% Adjustment Rate as New Honebuto Paper Nears Completion
  June 1, 2021

• Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
  February 9, 2021

• Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
  January 8, 2021

• Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near
  December 28, 2020

• Generic Makers Reorganizing Manufacturing Sites; Leveraging Their Strengths to Survive
  October 23, 2020

• IPOs or Sale? Employee Motivation Depends on Exit Strategies of Investment Funds
  September 16, 2020

• Sumitomo Dainippon Aims at 100 Billion Yen Sales from “Frontier Business,” Making Challenge Beyond Drugs
  September 9, 2020

• COVID-19 Pandemic to Test True Value of MHLW’s Officers with Medical/Pharma Backgrounds
  August 26, 2020

• COVID-19’s Impact on Pharma Becoming Clearer with New Data, Earnings
  August 17, 2020

• With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
  July 30, 2020

• Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
  July 22, 2020

• Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
  July 13, 2020

• Will Zolgensma Delay Spur Revision of Sakigake Designation System?
  June 11, 2020

• Establish Development Regime to Always Be Prepared for New Infectious Disease, Global Health Confab Urges amid COVID-19
  May 7, 2020

• Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
  April 27, 2020

ページ